Combined Hormone Therapy Worsens Migraines in Postmenopausal Women
A WHI trial analysis of 22,876 women finds estrogen-plus-progestin therapy significantly worsens headaches, especially in women with migraine history.
Summary
A large randomized trial analysis from the Women's Health Initiative found that the type of menopausal hormone therapy matters significantly for headache outcomes. Estrogen-only therapy was not linked to worsening headaches in postmenopausal women, regardless of migraine history. However, combined estrogen-plus-progestin therapy was associated with a 53% higher risk of worsening headache trajectory in women with prior migraine. Even women without a migraine history saw modestly increased headache severity on the combined therapy. These findings are clinically meaningful given how commonly hormone therapy is prescribed and how debilitating migraines can be. Physicians should consider headache history when choosing between hormone therapy formulations at menopause.
Detailed Summary
Migraine affects women at three times the rate of men and remains a significant source of disability throughout a woman's life. As women enter menopause, hormonal fluctuations can alter headache patterns, yet the impact of prescribed menopausal hormone therapy on postmenopausal headache severity has remained poorly characterized by randomized data — until now.
Researchers conducted a secondary analysis of two parallel, placebo-controlled randomized clinical trials within the Women's Health Initiative Hormone Therapy program, examining 22,876 postmenopausal women with an average age of 64 enrolled across the United States between 1993 and 1998. Participants were randomized to estrogen-only therapy, combined estrogen-plus-progestin therapy, or placebo. Changes in self-reported headache severity were tracked from baseline to one year, with particular attention to whether headache trajectories worsened over that period.
The results reveal a clear divergence between the two hormone formulations. Estrogen-only therapy was not associated with worsening headache severity or trajectory in either women with or without a migraine history. By contrast, combined estrogen-plus-progestin therapy was associated with a 53% increased risk of worsening headache trajectory among women with a prior migraine diagnosis — a statistically significant finding. Even among those without migraine history, combined therapy was associated with modestly increased odds of moderate-to-severe headache and a worsening trajectory.
These findings carry direct clinical implications: when counseling perimenopausal or postmenopausal women about hormone therapy options, migraine history should factor into the conversation. Women with a migraine history appear particularly vulnerable to headache worsening on combined estrogen-plus-progestin regimens.
Important caveats apply. Headache severity was self-reported, the study population was largely older postmenopausal women (average age 64), and the trials used older oral hormone formulations. Modern transdermal and lower-dose preparations may carry different risk profiles. The summary is based on the abstract only.
Key Findings
- Estrogen-only MHT was not associated with worsening headache severity or trajectory in postmenopausal women.
- Combined estrogen-plus-progestin MHT raised the risk of worsening headache trajectory by 53% in women with prior migraine.
- Even women without migraine history saw modest increases in headache severity on combined hormone therapy.
- 10% of the 22,876 trial participants reported a lifetime migraine diagnosis at baseline.
- Hormone therapy type — not just use — matters when managing postmenopausal headache risk.
Methodology
Secondary stratified analysis of two parallel randomized placebo-controlled WHI Hormone Therapy trials enrolling 22,876 postmenopausal women aged ~64 across the US (1993–1998). Headache severity was self-reported at baseline and year 1; analyses were adjusted for relevant covariates and stratified by migraine history.
Study Limitations
The summary is based on the abstract only, as the full text was not available. The study used older oral hormone formulations from the 1990s, so findings may not translate directly to modern transdermal or low-dose preparations. Headache outcomes were self-reported, which introduces potential measurement variability.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: